Claire Mazumdar sold $301k of BCAX
Chief Executive Officer at Bicara Therapeutics Inc.. 15,000 shares at an average of $20.04, traded May 18, 2026, filed May 20, 2026.
Score components
- +25RoleCEO
- +14Trade size$301k at market
- 0Share of holdings soldSold 4.0% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +13.7%, 3m +26.6%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-26-036885, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 18, 2026 | MOption exercise Common Stock10b5-1 | +15,000 | $3.79 | $57k | 377,152 | May 20, 2026 |
| May 18, 2026 | SOpen-market sale Common Stock10b5-1 | -12,022 | $19.96 | $240k | 365,130 | May 20, 2026 |
| May 18, 2026 | SOpen-market sale Common Stock10b5-1 | -2,978 | $20.35 | $61k | 362,152 | May 20, 2026 |
| May 18, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -15,000 | $0.00 | $0 | 146,107 | May 20, 2026 |
Related signals
Other insiders at Bicara Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 6Weak | Bicara Therapeutics Inc. | Ryan Cohlhepp President, COO & Interim CEO | $401k 17,500 shares | -9% | |
| 18Weak | Bicara Therapeutics Inc. | Ryan Cohlhepp President and COO | $525k 18,750 shares | -9% | |
| 19Weak | Bicara Therapeutics Inc. | Claire Mazumdar Chief Executive Officer | $280k 10,000 shares | -3% | |
| 17Weak | Bicara Therapeutics Inc. | Ivan Hyep Chief Financial Officer | $350k 12,500 shares | -9% | |
| 19Weak | Bicara Therapeutics Inc. | Claire Mazumdar Chief Executive Officer | $284k 10,000 shares | -3% | |
| 29Weak | Bicara Therapeutics Inc. | Ivan Hyep Chief Financial Officer | $808k 28,000 shares | -18% | |
| 28Weak | Bicara Therapeutics Inc. | Ryan Cohlhepp President and COO | $833k 28,750 shares | -14% | |
| 14Weak | Bicara Therapeutics Inc. | Ivan Hyep Chief Financial Officer | $188k 9,200 shares | -6% | |
| 13Weak | Bicara Therapeutics Inc. | Ryan Cohlhepp President and COO | $254k 12,500 shares | -6% | |
| 6Weak | Bicara Therapeutics Inc. | David Raben Chief Medical Officer | $126k 5,500 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.